Literature DB >> 18378336

BNP or NTproBNP? A clinician's perspective.

Johannes Steiner1, Maya Guglin.   

Abstract

Existing literature on two natriuretic peptides--B-type natriuretic peptide (BNP) and amino terminal pro-brain natriuretic peptide (NTproBNP)--is overwhelming. Both peptides are acknowledged markers for cardiac dysfunction. Most of the sources present data on either BNP or NTproBNP making the comparison difficult. This paper focuses on reviewing studies directly comparing two peptides in the setting of chronic and acute heart failure (HF) and coronary artery disease. Many concomitant diseases influence these two peptides to varying extent. These characteristics should be taken into consideration when interpreting results. For most practical purposes, BNP and NTproBNP are interchangeable, and can be used based on local preferences and availability. NTproBNP seems to be more advantageous for diagnosing mild HF or asymptomatic left ventricular dysfunction.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18378336     DOI: 10.1016/j.ijcard.2007.12.093

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  16 in total

1.  B-type natriuretic peptide increases after gastric bypass surgery and correlates with weight loss.

Authors:  Eric M Changchien; Shushmita Ahmed; Francesca Betti; Jennifer Higa; Kate Kiely; Tina Hernandez-Boussard; John Morton
Journal:  Surg Endosc       Date:  2011-03-18       Impact factor: 4.584

2.  Diagnostic values of NT-proBNP in acute dyspnea among elderly patients.

Authors:  Qin Su; Hongsheng Liu; Xian Zhang; Wei Dang; Runmei Liu; Xiaodong Zhao; Xiaoling Yuan; Yuhong Qin; Jianbo Zhang; Chunming Chen; Yunfeng Xia
Journal:  Int J Clin Exp Pathol       Date:  2015-10-01

3.  Serum brain natriuretic peptide in children with Kawasaki disease.

Authors:  Yu-Ping Sun; Chao-Ping Wei; Wen-di Wang; Xing-Chang Zheng; Ye-Jun Wang; Shao-Chun Ma; Ying-Jun Xu
Journal:  World J Emerg Med       Date:  2010

4.  Association between obstructive sleep apnea and elevated levels of type B natriuretic peptide in a community-based sample of women.

Authors:  Mirjam Ljunggren; Bertil Lindahl; Jenny Theorell-Haglöw; Eva Lindberg
Journal:  Sleep       Date:  2012-11-01       Impact factor: 5.849

5.  Pro-brain natriuretic peptide (ProBNP) levels in North Indian children with Kawasaki disease.

Authors:  Mounika Reddy; Surjit Singh; Amit Rawat; Avinash Sharma; Deepti Suri; Manoj Kumar Rohit
Journal:  Rheumatol Int       Date:  2016-02-05       Impact factor: 2.631

6.  Influence of preoperative serum N-terminal pro-brain type natriuretic peptide on the postoperative outcome and survival rates of coronary artery bypass patients.

Authors:  Thomas Schachner; Dominik Wiedemann; Hannes Fetz; Guenther Laufer; Alfred Kocher; Nikolaos Bonaros
Journal:  Clinics (Sao Paulo)       Date:  2010       Impact factor: 2.365

7.  Determination and stability of N-terminal pro-brain natriuretic peptide in saliva samples for monitoring heart failure.

Authors:  Francesca G Bellagambi; Christina Petersen; Pietro Salvo; Silvia Ghimenti; Maria Franzini; Denise Biagini; Marie Hangouët; Maria Giovanna Trivella; Fabio Di Francesco; Aldo Paolicchi; Abdelhamid Errachid; Roger Fuoco; Tommaso Lomonaco
Journal:  Sci Rep       Date:  2021-06-22       Impact factor: 4.379

8.  Perioperative application of N-terminal pro-brain natriuretic peptide in patients undergoing cardiac surgery.

Authors:  Hua Liu; Chunsheng Wang; Lan Liu; Yamin Zhuang; Xiaomei Yang; Ying Zhang
Journal:  J Cardiothorac Surg       Date:  2013-01-07       Impact factor: 1.637

9.  NT-ProBNP levels are moderately increased in acute high-altitude pulmonary edema.

Authors:  Mingdong Gao; Ruimin Wang; Zepei Jiayong; Yin Liu; Genyi Sun
Journal:  Exp Ther Med       Date:  2013-02-26       Impact factor: 2.447

10.  Natriuretic peptide-guided therapy in chronic heart failure: a meta-analysis of 2,686 patients in 12 randomized trials.

Authors:  Gianluigi Savarese; Bruno Trimarco; Santo Dellegrottaglie; Maria Prastaro; Francesco Gambardella; Giuseppe Rengo; Dario Leosco; Pasquale Perrone-Filardi
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.